Generic Name for OPTIRAY 350
Ioversol 741mg/mL; soln for intravascular administration; contains organically bound iodine 350mg per mL.
Legal Classification:
Rx
Pharmacological Class for OPTIRAY 350
Radiopaque contrast agent.
Manufacturer of OPTIRAY 350
Mallinckrodt, Inc.
|
Indications for OPTIRAY 350
Adults: Peripheral and coronary arteriography and left ventriculography. For contrast enhanced computed tomographic imaging of the head and body. IV excretory urography. IV digital subtraction angiography and venography. Children: Angiocardiography.
Adult dose for OPTIRAY 350
Individualize. Peripheral arteriography: Aortic-iliac runoff: 60mL (range 20–90mL); Common iliac, femoral: 40mL (range 10–50mL); Subclavian, brachial: 20mL (15–30mL); total procedure doses should not exceed 250mL. Coronary arteriography and left ventriculography: Left coronary: 8mL (range 2–10mL); Right coronary: 6mL (range 1–10mL); Left ventricle: 40mL (range 30–50mL); max dose for procedures 250mL. Venography: 50–100mL per extremity; max 250mL. Head imaging: 50–150mL; max 150mL. Body imaging: Bolus inj: 25–75mL; Infusion: 50–150mL; max 150mL. IV digital subtraction angiography: may be injected centrally, in either the superior or inferior vena cava, or right atrium; or peripherally into an appropriate arm vein. Usual range: 30–50mL; total procedure dose should not exceed 250mL. IV urography: 50–75mL; may use higher dose of 1.4mL/kg (max 140mL) for optimum results.
Children's dosing for OPTIRAY 350
Angiocardiography: 1.25mL/kg (range 1–1.5mL/kg); total administered dose should not exceed 5mL/kg up to a volume of 250mL.
Also:
Warnings/Precautions for OPTIRAY 350
Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Avoid angiography with homocystinuria. Suspected thrombosis, phlebitis, severe ischemic disease, local infection: caution with venography. Renal or hepatic impairment. Anuria. CHF. Pulmonary hypertension. Multiple myeloma or other paraproteinemia. Homozygous sickle cell disease. Pheochromocytoma. Thyroid disorder. Diabetes. Myasthenia gravis. Anesthetized patients. Monitor blood pressure. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy (Cat.B). Nursing mothers.
Interactions for OPTIRAY 350
Patients with hepatic or biliary disorder that have received cholecystographic agents recently; increased risk of renal toxicity. Do not mix with other drugs. Radioactive iodine uptake studies may not accurately reflect thyroid function for up to 16 days.
Adverse Reactions for OPTIRAY 350
Nausea, headache; cardiovascular, CNS, respiratory, skin reactions (see literature).
How is OPTIRAY 350 supplied?
OPTIRAY 240: Bottles (50mL)—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 125mL)—20, RFID-Tagged syringes (125ml)—20; OPTIRAY 300: Bottles (50mL—25, 100mL—12, 150mL—12, 200mL—12, Syringes (50mL, 100mL, 125mL)—20, RFID-Tagged syringes (100mL, 125mL)—20; OPTIRAY 320: Vials (20mL, 30mL)—25, Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (30mL, 50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 75mL, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (50mL, 75mL, 100mL, 125mL)—20